21Shares launches JitoSOL-based Solana staking ETP in Europe
21Shares has launched a new exchange-traded product that combines exposure to Solana with liquid staking, expanding the range of crypto yield products available to European investors.
The firm said Thursday that its 21Shares Jito Staked SOL ETP, trading under the ticker JSOL, gives investors exchange-traded access to JitoSOL, one of the dominant liquid staking tokens on the Solana network. Holding JitoSOL allows investors to retain full exposure to the price of SOL while earning two sources of yield: standard staking rewards and an additional share of transaction-related revenue generated through Jito’s infrastructure on Solana. The structure enables investors to access staking returns without managing wallets, validators, or onchain operations.
According to a statement, the product is listed on Euronext Amsterdam and Paris in U.S. dollar and euro denominations and carries a total expense ratio of 0.99%.
Solana’s low fees and high throughput have drawn attention from both crypto-native firms and traditional financial institutions like Visa, PayPal, and Franklin Templeton, exploring and diving into onchain settlement.
Alistair Byas-Perry, head of EU investments and capital markets at 21Shares, said the product expands on the firm’s previously introduced staking features within its Solana ETP lineup and that the manager sees continued demand for yield-enhanced crypto exposure.
Brian Smith, president of the Jito Foundation, added that the collaboration reflects growing institutional interest in Solana as onchain activity scales beyond experimentation and into payments, trading, and tokenization use cases. "JitoSOL was built from the ground up to provide liquidity and full staking exposure without compromising on transparency or network alignment," he said.
The product adds to Europe’s growing lineup of crypto ETPs that incorporate staking features. Meanwhile, in the U.S., asset managers and regulators continue actively discussing how staking, yield, and validator economics should be treated within ETF and ETP structures, including proposals tied to JitoSOL and other staking tokens.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
